152 related articles for article (PubMed ID: 26735176)
21. Obatoclax and LY3009120 Efficiently Overcome Vemurafenib Resistance in Differentiated Thyroid Cancer.
Wei WJ; Sun ZK; Shen CT; Song HJ; Zhang XY; Qiu ZL; Luo QY
Theranostics; 2017; 7(4):987-1001. PubMed ID: 28382170
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib inhibits MEK/ERK and SAPK/JNK pathways and increases sodium/iodide symporter expression in papillary thyroid cancer.
Fenton MS; Marion KM; Salem AK; Hogen R; Naeim F; Hershman JM
Thyroid; 2010 Sep; 20(9):965-74. PubMed ID: 20629553
[TBL] [Abstract][Full Text] [Related]
23. A constitutive active MAPK/ERK pathway due to BRAFV600E positively regulates AHR pathway in PTC.
Occhi G; Barollo S; Regazzo D; Bertazza L; Galuppini F; Guzzardo V; Jaffrain-Rea ML; Vianello F; Ciato D; Ceccato F; Watutantrige-Fernando S; Bisognin A; Bortoluzzi S; Pennelli G; Boscaro M; Scaroni C; Mian C
Oncotarget; 2015 Oct; 6(31):32104-14. PubMed ID: 26392334
[TBL] [Abstract][Full Text] [Related]
24. Vemurafenib resistance selects for highly malignant brain and lung-metastasizing melanoma cells.
Zubrilov I; Sagi-Assif O; Izraely S; Meshel T; Ben-Menahem S; Ginat R; Pasmanik-Chor M; Nahmias C; Couraud PO; Hoon DS; Witz IP
Cancer Lett; 2015 May; 361(1):86-96. PubMed ID: 25725450
[TBL] [Abstract][Full Text] [Related]
25. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
26. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
27. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
[TBL] [Abstract][Full Text] [Related]
28. A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.
Plews RL; Mohd Yusof A; Wang C; Saji M; Zhang X; Chen CS; Ringel MD; Phay JE
J Clin Endocrinol Metab; 2015 May; 100(5):E748-56. PubMed ID: 25710562
[TBL] [Abstract][Full Text] [Related]
29. Activation of the JAK/STAT Pathway Leads to BRAF Inhibitor Resistance in BRAFV600E Positive Thyroid Carcinoma.
Limberg J; Egan CE; Gray KD; Singh M; Loewenstein Z; Yang Y; Riascos MC; Al Asadi H; Safe P; El Eshaky S; Liang H; Ullmann TM; Wang W; Li W; Zhang T; Xiang J; Stefanova D; Jin MM; Zarnegar R; Fahey TJ; Min IM
Mol Cancer Res; 2023 May; 21(5):397-410. PubMed ID: 36790391
[TBL] [Abstract][Full Text] [Related]
30. Resistance to Selumetinib (AZD6244) in colorectal cancer cell lines is mediated by p70S6K and RPS6 activation.
Grasso S; Tristante E; Saceda M; Carbonell P; Mayor-López L; Carballo-Santana M; Carrasco-García E; Rocamora-Reverte L; García-Morales P; Carballo F; Ferragut JA; Martínez-Lacaci I
Neoplasia; 2014 Oct; 16(10):845-60. PubMed ID: 25379021
[TBL] [Abstract][Full Text] [Related]
31. XB130, a tissue-specific adaptor protein that couples the RET/PTC oncogenic kinase to PI 3-kinase pathway.
Lodyga M; De Falco V; Bai XH; Kapus A; Melillo RM; Santoro M; Liu M
Oncogene; 2009 Feb; 28(7):937-49. PubMed ID: 19060924
[TBL] [Abstract][Full Text] [Related]
32. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition.
Deng W; Gopal YN; Scott A; Chen G; Woodman SE; Davies MA
Pigment Cell Melanoma Res; 2012 Mar; 25(2):248-58. PubMed ID: 22171948
[TBL] [Abstract][Full Text] [Related]
33. Activation of mTOR signaling in medullary and aggressive papillary thyroid carcinomas.
Kouvaraki MA; Liakou C; Paraschi A; Dimas K; Patsouris E; Tseleni-Balafouta S; Rassidakis GZ; Moraitis D
Surgery; 2011 Dec; 150(6):1258-65. PubMed ID: 22136849
[TBL] [Abstract][Full Text] [Related]
34. Small molecule c-MET inhibitor PHA665752: effect on cell growth and motility in papillary thyroid carcinoma.
Chattopadhyay C; El-Naggar AK; Williams MD; Clayman GL
Head Neck; 2008 Aug; 30(8):991-1000. PubMed ID: 18327775
[TBL] [Abstract][Full Text] [Related]
35. Cellular apoptosis susceptibility (CAS) is overexpressed in thyroid carcinoma and maintains tumor cell growth: A potential link to the BRAFV600E mutation.
Holzer K; Drucker E; Oliver S; Winkler J; Eiteneuer E; Herpel E; Breuhahn K; Singer S
Int J Oncol; 2016 Apr; 48(4):1679-87. PubMed ID: 26892809
[TBL] [Abstract][Full Text] [Related]
36. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling.
Mu DW; Guo HQ; Zhou GB; Li JY; Su B
Int J Clin Exp Pathol; 2015; 8(11):13864-70. PubMed ID: 26823699
[TBL] [Abstract][Full Text] [Related]
37. BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation.
Palona I; Namba H; Mitsutake N; Starenki D; Podtcheko A; Sedliarou I; Ohtsuru A; Saenko V; Nagayama Y; Umezawa K; Yamashita S
Endocrinology; 2006 Dec; 147(12):5699-707. PubMed ID: 16959844
[TBL] [Abstract][Full Text] [Related]
38. Akt inhibition enhances the cytotoxic effect of apigenin in combination with PLX4032 in anaplastic thyroid carcinoma cells harboring BRAFV600E.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
J Endocrinol Invest; 2013 Dec; 36(11):1099-104. PubMed ID: 24084189
[TBL] [Abstract][Full Text] [Related]
39. Genome-wide analysis of differentially expressed miRNA in PLX4720-resistant and parental human thyroid cancer cell lines.
Varmeh S; Vanden Borre P; Gunda V; Brauner E; Holm T; Wang Y; Sadreyev RI; Parangi S
Surgery; 2016 Jan; 159(1):152-62. PubMed ID: 26456124
[TBL] [Abstract][Full Text] [Related]
40. Computational modeling reveals MAP3K8 as mediator of resistance to vemurafenib in thyroid cancer stem cells.
Gianì F; Russo G; Pennisi M; Sciacca L; Frasca F; Pappalardo F
Bioinformatics; 2019 Jul; 35(13):2267-2275. PubMed ID: 30481266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
